HbA1c:Review of Standardisation and Quality Management

doi:10.3969/j.issn.1673-8640.2013.10.001

检验医学 ›› 2013, Vol. 28 ›› Issue (10): 867-872.DOI: 10.3969/j.issn.1673-8640.2013.10.001

• 专家论坛 • 下一篇

HbA_1c:Review of Standardisation and Quality Management

CasWeykamp

Queen Beatrix Hospital，Winterswijk Netherlands

收稿日期:2013-08-12 出版日期:2013-10-30 发布日期:2013-10-29
作者简介:CasWeykamp博士，现任荷兰贝娅特丽克丝女王医院的临床化学家、荷兰室间质评计划负责人、IFCCHbA_1c参考实验室网络联络官、IFCCHbA_1c整合计划成员、美国AACC一致性计划研发组主席、NGSP执行委员会成员、上海市临床检验中心学术顾问，是国际知名的糖化血红蛋白研究专家，致力于建立HbA_1c参考体系、推进HbA_1c检测的全球标准化。

Received:2013-08-12 Online:2013-10-30 Published:2013-10-29

摘要/Abstract

摘要：

糖化血红蛋白(HbA_1c)目前被认为是患者长期血糖控制和监测的金标准。2010年起，相继被美国糖尿病学会(ADA)、国际糖尿病联盟(IDF)、美国临床内分泌医师学会(AACE)、欧洲糖尿病研究学会(EASD)和世界卫生组织(WHO)等纳入糖尿病的诊断标准。在临床实验室中检测HbA_1c主要有阳离子交换色谱、亲和色谱、免疫比浊、电泳、酶化学和即时检验(POCT)等方法，检测结果间存在较大差异。自1993年起，国际临床化学联盟(IFCC)成立的HbA_1c标准化工作组和美国AACC建立的国家糖化血红蛋白标准化计划(NGSP)一起，致力于实现HbA_1c检测的标准化。本文全面介绍了HbA_1c的标准化、质量管理以及未来发展。

Key words: Glycated hemoglobin A_1c, Diabetes, Standardisation, Quality management

中图分类号:

R446.1

Cas Weykamp. HbA_1c:Review of Standardisation and Quality Management[J]. 检验医学, 2013, 28(10): 867-872.

参考文献

[1] World Health Organization. WHO diabetes media centre[EB/OL]. (2013-03-01) [2013-08-10]. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.
[2] American Diabetes Association. Economic costs of diabetes in the U.S. in 2007[J]. Diabetes Care,2008,31(6):1271.
[3] The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. N Eng J Med,1993,329(14):977-986.
[4] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]. Lancet,1998,352(9131):837-853.
[5] White NH, Sun W, Cleary PA, et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents[J]. Diabetes,2010,59(5):1244-1253.
[6] Weykamp C, John WG, Mosca A. A review of the challenge in measuring hemoglobin A1c[J]. J Diabetes Sci Technol,2009,3(3):439-445.
[7] Jaisson S, Leroy N, Meurice J, et al. First evaluation of Capillarys 2 Flex Piercing^○R (Sebia) as a new analyzer for HbA1c assay by capillary electrophoresis[J]. Clin Chem lab Med,2012,50(10):1769-1775.
[8] Mallia AK, Hermanson GT, Krohn RI, et al. Preparation and use of a boronic acid affinity support for separation and quantisation of glycosylated haemoglobin[J]. Anal Lett,1981,14:649-661.
[9] John WG, Gray MR, Bates DL, et al. Enzyme immunoassay-a new technique for estimating haemoglobin A1c[J]. Clin Chem,1993,39(4):663-666.
[10] Liu L, Hood S, Wang Y, et al. Direct enzymatic assay for % HbA1c in human whole blood samples[J]. Clin Biochem,2008,41(7-8):576-83.
[11] Greg Miller W, Myers GL, Lou Gantzer M, et al. Roadmap for harmonization of clinical laboratory measurement procedures[J]. Clin Chem,2011,57(8):1108-1117.
[12] Little RR, Rohlfing CL, Wiedmeyer HM, et al. The national glycohemoglobin standardization program: a five-year progress report[J]. Clin Chem,2001,47(11):1985-1992.
[13] Shima K, Endo J, Oimomi M, et al. Interlaboratory differences in GHb measurement in Japan, the fifth report of the GHb standardisation committee, the Japan Diabetes Society[J]. J Jap Diab Soc,1998,41:317-333.
[14] Jeppsson JO, Jerntorp P, Sundkvist G, et al. Measurement of haemoglobin A1c by a new liquid-chromatographic assay: methodology, clinical utility and relation to glucose tolerance evaluated[J]. Clin Chem,1986,32(10):1867-1872.
[15] Jeppsson JO, Kobold U, Barr J, et al. Approved IFCC reference method for the measurement of HbA1c in human blood[J]. Clin Chem Lab Med,2002,40(1):78-89.
[16] Weykamp C, John WG, Mosca A, et al. The IFCC reference measurement system for HbA1c: a 6 year progress report[J]. Clin Chem,2008,54(2):240-248.
[17] Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1c measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine and International Diabetes Federation[J]. Diabetes Care,2007,30(9): 2399-2400.
[18] American Diabetes Association. Standards of medical care in diabetes-2011[J]. Diabetes Care,2011,34(Suppl 1):S11-S61.
[19] American Diabetes Association. Standards of medical care in diabetes-2010[J]. Diabetes Care,2010,33(Suppl 1):S11-S61.
[20] Little RR, Rohlfing CL, Tennill AL, et al. Effects of sample storage conditions on glycated haemoglobin measurement: evaluation of five different high performance liquid chromatography methods[J]. Diabetes Technol Ther,2007,9(1):36-42.
[21] Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J]. Clin Chem,2011,57(6):e1-e47.
[22] Little RR, Rohlfing CL, Sacks DB. Status of hemoglobin HbA1c measurement and goals for improvement: from chaos to order for improving diabetes care[J]. Clin Chem,2011,57(2):205-214.
[23] Lenters-Westra E, Slingerland RJ. Six of eight haemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria[J]. Clin Chem,2010,56(1):44-52.

HbA_1c:Review of Standardisation and Quality Management

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	范列英. 膜性肾病生物标志物的研究现状与应用展望[J]. 检验医学, 2023, 38(12): 1111-1114.
[2]	孙林成, 李建锋, 程维丽, 姬攀云. 抗PLA2R IgG4抗体、PLA2R IgG4/IgG比值在原发性膜性肾病预后评估中的价值[J]. 检验医学, 2023, 38(12): 1115-1120.
[3]	刘庆阳, 袁建明, 夏进军, 姜风英, 王秋波, 王晓明. 基于GEO数据库和临床样本验证CXCL9作为类风湿关节炎生物标志物的研究[J]. 检验医学, 2023, 38(12): 1121-1129.
[4]	杨晓, 李恩灵, 吴丽霞, 戴颖欣, 王之青, 黄昊, 郑冰. 胞质型抗核抗体对间接免疫荧光法检测抗中性粒细胞胞质抗体的影响[J]. 检验医学, 2023, 38(12): 1135-1140.
[5]	项瑾, 刘爱平, 胡尧, 吴之源, 曹国君, 关明. 新型冠状病毒肺炎患者抗核抗体谱分析和血清加热灭活对检测的影响[J]. 检验医学, 2023, 38(12): 1141-1146.
[6]	成宇, 徐臻, 陆柳, 丁梦蕾, 虞珊珊, 宗明, 范列英. 新型冠状病毒肺炎患者血清抗ACE-2抗体表达及其影响因素分析[J]. 检验医学, 2023, 38(12): 1147-1152.
[7]	游延军, 张欢, 向乾银, 曹长春, 王健, 曾红, 魏元敏, 吴斌, 黄敬双, 季纯宇, 代苗, 秦枫. 原发性膜性肾病标志物抗PLA2R抗体检测方法比较[J]. 检验医学, 2023, 38(12): 1153-1156.
[8]	王丽, 陈琳, 黄卓春. 易误判的ANA荧光模型1例报道[J]. 检验医学, 2023, 38(12): 1157-1159.
[9]	王洪玲, 刘梦娜, 白萍, 廖焕金. AML患者异基因造血干细胞移植后复发危险因素分析[J]. 检验医学, 2023, 38(12): 1160-1166.
[10]	杨茜岚, 汪金玉, 刘舒予, 占伊扬, 刘菁, 贾坚. 南京市鼓楼社区老年人群高脂血症与内皮细胞微粒的相关性[J]. 检验医学, 2023, 38(12): 1167-1172.
[11]	代芳芳, 鲁辛辛, 于艳华, 陈铭, 孙桂珍. HIV/AIDS患者分枝杆菌检出情况分析[J]. 检验医学, 2023, 38(12): 1173-1176.
[12]	顾玉, 梁晓艳, 马胜辉, 佟娜, 程明艳, 阎泽君. 血浆生物标志物在慢性肾脏病伴血栓栓塞患者中的表达及其近期预后评估价值[J]. 检验医学, 2023, 38(12): 1177-1182.
[13]	周维, 诸佩超, 宋颖, 缪颖波, 赵强, 徐翀. 抗Xa因子活性室间质量评价调查品制备及应用[J]. 检验医学, 2023, 38(12): 1183-1185.
[14]	努荣古丽·买买提, 衡燕, 张凯迪, 王新玲, 李慧, 杜丹阳, 董玲玲, 郭艳英. 乌鲁木齐地区成年男性骨代谢指标与代谢综合征的相关性分析[J]. 检验医学, 2023, 38(12): 1186-1190.
[15]	李文静, 陆书华, 李晓哲, 戈宁宁, 董海新. 非O1/非O139群霍乱弧菌血流感染病原学和临床特征[J]. 检验医学, 2023, 38(12): 1191-1194.